Orforglipron
vs Tirzepatide.
Compare FDA-approved Foundayo and Zepbound by daily pill versus weekly injection, mechanism, label results, approved uses, and cross-trial limits.
Also searched as Foundayo vs Zepbound · orforglipron vs tirzepatide · pill vs weekly injection
What is the difference?
Foundayo and Zepbound are FDA-approved US products for defined adult weight-management populations, but they differ in molecule, mechanism, route, schedule, labeled uses, and evidence. Foundayo contains the non-peptide small molecule orforglipron, activates the GLP-1 receptor, and is taken as a once-daily tablet. Zepbound contains the peptide tirzepatide, activates GIP and GLP-1 receptors, and is injected once weekly. Their labels report results from separate 72-week studies, not a randomized comparison. Foundayo's highest approved equivalent-dose group averaged about 11.1% weight reduction, while Zepbound Study 1 reported up to 20.9%. That cross-trial difference does not establish a winner.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Orforglipron
FDA-approved prescription drug
- Route
- Oral
- Registry
- Dedicated medicine evidence record
- Sponsor
- Lilly USA, LLC
Tirzepatide
FDA-approved prescription drug
- Route
- Subcutaneous
- Registry
- Dedicated medicine evidence record
- Sponsor
- Lilly USA, LLC
Orforglipron vs Tirzepatide: how direct is the evidence?
No participant in the cited sources was randomized between Orforglipron and Tirzepatide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Orforglipron
Non-peptide small-molecule GLP-1 receptor agonist
- Route
- Oral
- Stage
- NDA 220934 approved product record
- Status
- FDA-approved prescription drug
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialTirzepatide
GIP and GLP-1 receptor agonist
- Route
- Subcutaneous
- Stage
- NDA 217806 approved product record
- Status
- FDA-approved prescription drug
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
Outside this 13-program snapshot
This comparison uses an approved-medicine record here. A blank is a scope boundary, not evidence that no clinical trial or trial history exists.
Open the bounded clinical trial finder →Outside this 13-program snapshot
This comparison uses an approved-medicine record here. A blank is a scope boundary, not evidence that no clinical trial or trial history exists.
Open the bounded clinical trial finder →Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Orforglipron
Non-peptide small-molecule GLP-1 receptor agonist
- Route
- Oral
- Stage
- NDA 220934 approved product record
- Status
- FDA-approved prescription drug
- Featured trial anchors
- NDA 220934
Tirzepatide
GIP and GLP-1 receptor agonist
- Route
- Subcutaneous
- Stage
- NDA 217806 approved product record
- Status
- FDA-approved prescription drug
- Featured trial anchors
- NDA 217806
Compare the field, then read the limit.
The search usually combines a convenience question with an efficacy question: whether a daily pill is preferable to a weekly injection and whether the larger headline percentage means a better drug. The labels can answer molecular class, route, receptor strategy, schedule, study design, approved population, warnings, and current uses. They cannot establish comparative benefit, safety, adherence, cost, or suitability for an individual because the products were not tested against each other in the same randomized protocol.
| Field | Orforglipron | Tirzepatide | How to interpret it |
|---|---|---|---|
| Molecular identity | Non-peptide small-molecule GLP-1 receptor agonist | Peptide GIP and GLP-1 receptor agonist | The products engage overlapping biology through different molecules and receptor strategies, which does not make them interchangeable. |
| Route and schedule | Once-daily oral FOUNDAYO tablet | Once-weekly subcutaneous ZEPBOUND injection | Convenience and preference depend on the complete regimen and individual circumstances, not route or frequency alone. |
| Weight-evidence anchor | About 11.1% at 72 weeks in the highest approved equivalent-dose group | Up to 20.9% at 72 weeks in ZEPBOUND Study 1 | The matching duration is not a head-to-head design; different protocols and placebo responses prevent a valid numerical winner claim. |
| Labeled-use distinction | Weight management in a defined adult population | Weight management plus moderate-to-severe obstructive sleep apnea in defined adults with obesity | Zepbound's additional OSA indication belongs to its exact label and does not imply broader superiority for every clinical question. |
| Current US record | FOUNDAYO under NDA 220934 | ZEPBOUND under NDA 217806 | Each approval belongs to its reviewed tablets or injections, company, manufacturing record, indication, warnings, and prescribing information. |
Why the headline numbers do not name a winner.
Foundayo Trial 1 reports about 11.1% mean weight reduction at 72 weeks for the highest approved equivalent-dose group versus 2.1% with placebo. Zepbound Study 1 reports 15.0%, 19.5%, and 20.9% for the 5 mg, 10 mg, and 15 mg groups at 72 weeks versus 3.1% with placebo. The protocols used different molecules, populations, escalation plans, discontinuation patterns, and statistical handling. Equal duration does not create shared randomization, so the percentages cannot prove superiority or predict the same outcome in another population.
Keep the comparison honest.
- 01
Keep the molecular and receptor distinctions explicit: orforglipron is a non-peptide GLP-1 agonist, while tirzepatide is a peptide GIP and GLP-1 agonist.
- 02
Attach every percentage to the exact label study, population, dose, duration, placebo response, and analysis instead of treating equal duration as shared evidence.
- 03
Treat FOUNDAYO and ZEPBOUND as exact FDA-approved products, while separating their records from compounded, imported, or online products using the ingredient names.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →